Maxim Group Raises Gilead Sciences Price Target to $200
Maxim Group has increased its price target for Gilead Sciences (GILD) from $165 to $200.
Stocks · News reference
Gilead Sciences Announces Phase 3 IDEAL Study Results for Livdelzi in PBC
Gilead Sciences reported positive results from its Phase 3 IDEAL study, showing that a majority of patients with Primary Biliary Cholangitis (PBC) treated with Livdelzi (seladelpar) achieved alkaline phosphatase (ALP) normalization.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
Gilead Sciences increased its quarterly dividend by 3.8% to $0.82, marking the 11th consecutive year of dividend increases. The company's strong HIV franchise generated 18% higher sales year-over-year, while its oncology expansion shows promise with Trodelvy reporting 42% sales growth. With a low payout ratio of 29.8%, Gilead has ample room to sustain dividend growth and fund $32 billion in research projects through 2030.
Gilead Sciences and Kite Announce Clinical Data Presentations for ASH 2026
Gilead Sciences and its subsidiary Kite announced that they will present 23 clinical data updates at the 68th American Society of Hematology (ASH) Annual Meeting.
Gilead Sciences To Present 23 Presentations At 68th American Society of Hematology Annual Meeting
DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
DZ Bank has increased its price target for Gilead Sciences, moving it from $167 to $191.
FDA Approves Long-Acting HIV Prevention Drug
The U.S. FDA has approved a long-acting injectable version of Gilead Sciences' lenacapavir for the prevention of HIV.